Janney Montgomery Scott LLC Has $1.14 Million Holdings in Zynex Inc. $ZYXI

Janney Montgomery Scott LLC increased its stake in Zynex Inc. (NASDAQ:ZYXI) by 195.3% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 440,177 shares of the company’s stock after purchasing an additional 291,134 shares during the period. Janney Montgomery Scott LLC owned 1.46% of Zynex worth $1,136,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in ZYXI. Goldman Sachs Group Inc. increased its position in shares of Zynex by 118.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 170,718 shares of the company’s stock valued at $376,000 after buying an additional 92,463 shares in the last quarter. Nuveen LLC acquired a new position in shares of Zynex during the 1st quarter worth about $110,000. Jane Street Group LLC boosted its stake in shares of Zynex by 239.9% during the 1st quarter. Jane Street Group LLC now owns 53,377 shares of the company’s stock worth $117,000 after buying an additional 37,673 shares during the last quarter. Hsbc Holdings PLC acquired a new position in shares of Zynex during the 1st quarter worth about $53,000. Finally, Corton Capital Inc. acquired a new stake in Zynex in the 1st quarter valued at about $52,000. Institutional investors own 29.68% of the company’s stock.

Zynex Price Performance

Shares of NASDAQ ZYXI opened at $1.38 on Tuesday. The company has a current ratio of 0.62, a quick ratio of 0.45 and a debt-to-equity ratio of 0.56. The firm’s 50-day moving average price is $1.52 and its 200-day moving average price is $2.02. The firm has a market capitalization of $41.81 million, a P/E ratio of -1.47 and a beta of 1.10. Zynex Inc. has a 1-year low of $1.23 and a 1-year high of $9.42.

Wall Street Analyst Weigh In

ZYXI has been the topic of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Zynex in a report on Wednesday, October 8th. Royal Bank Of Canada lowered their target price on shares of Zynex from $4.00 to $3.00 and set a “sector perform” rating on the stock in a report on Tuesday, July 15th. LADENBURG THALM/SH SH raised shares of Zynex from a “neutral” rating to a “buy” rating and set a $3.70 target price on the stock in a report on Friday, August 1st. Finally, HC Wainwright lowered shares of Zynex from a “buy” rating to a “neutral” rating in a research report on Friday, August 1st. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Zynex currently has an average rating of “Hold” and a consensus price target of $4.90.

Zynex Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.